Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?

Bulletin of the World Health Organization

Volumn 82, Issue 11, 2004, Pages 815-821

  Oliveira, Maria Auxiliadora ^a   Bermudez, Jorge Antonio Zepeda ^a   Chaves, Gabriela Costa ^a   Velásquez, Germán ^b  

^a Natl Sch Pub Hlth O Cruz F   (Brazil)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Developing countries; Drug and narcotic control methods; Drug industry; Drugs, Generic supply and distribution; Latin America; Licensure legislation; Patents legislation; Pharmaceutical preparations supply and distribution; Policy making; Treaties

Indexed keywords

GENERIC DRUG; NARCOTIC AGENT;

INTELLECTUAL PROPERTY RIGHTS; PHARMACEUTICAL INDUSTRY; PUBLIC HEALTH; TRADE AGREEMENT;

ARTICLE; CARIBBEAN ISLANDS; DEVELOPING COUNTRY; DRUG MANUFACTURE; GOVERNMENT; HEALTH CARE POLICY; LAW; LICENSING; PATENT; PUBLIC HEALTH; SOUTH AND CENTRAL AMERICA; STANDARD;

CARIBBEAN REGION; COMMERCE; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, ESSENTIAL; ECONOMIC COMPETITION; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL AGENCIES; INTERNATIONAL COOPERATION; LATIN AMERICA; PATENTS; PUBLIC HEALTH; SOCIAL JUSTICE;

ATLANTIC ISLANDS; ATLANTIC OCEAN; CARIBBEAN ISLANDS; LATIN AMERICA; OCEANIC REGIONS; WESTERN HEMISPHERE; WORLD;

EID: 9644272570     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. World Trade Organization. Agreement on trade-related aspects of intellectual property rights. Geneva: Word Trade Organization; 1995. (Also available from: http://www.wto.org/english/docs_e/legal_e/27-trips.pdf)
2. Velásquez G, Boulet P. Globalization and access to drugs: implications of the WTO/TRIPS agreement. Geneva: World Health Organization; 1999. (Also available from: http://www.who.int/medicines/library/dap/who-dap-98- 9-rev/who-dap-98-9rev.pdf)
3. World Trade Organization. Doha WTO ministerial: ministerial declaration 2001. Geneva; WTO; 2001 (Document No, WT/MIN(01)/DEC/2(2001)). (Also available from: http://www.wto.org/english/thewto_e/minist_e/min01_e/minded_e.htm)
4. Commission on Intellectual Property Rights. Integrating intellectual property rights and development policy. London: Commission on Intellectual Property Rights; 2002.
5. T'Hoen E. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. Chicago Journal International of Law 2002;3:27-48.
6. Bermudez JAZ, Epsztejn R, Oliveira MA, Hasenclever L. The WTO TRIPS Agreement and patent protection in Brazil: recent changes and implications for local production and access to medicines. Rio de Janeiro: Fiocruz; 2000.
7. Supakankunti S, Janjaroen WS, Tangphao O, Ratanawijitrasin S, Kraipornsak P, Pradithavanij P. Impact of the World Trade Organization TRIPS Agreement on the pharmaceutical industry in Thailand. Bulletin of the World Health Organization 2001;79:461-70.
8. Bailey M, Mayne R. Priced out of reach: how WTO patent policies will reduce access to medicines in the developing world. Washington (DC): Oxfam International; 2001 (Briefing paper No. 4). (Also available from: http://www.oxfam.org.uk/what_we_do/issues/health/bp04_priced.htm)
9. Management Sciences for Health, World Health Organization. Managing drug supply. West Hartford (CT): Kumarian Press; 1997.
10. National Institute for Health Care Management. Changing patterns of pharmaceutical innovation. Washington (DC): National Institute for Health Care Management; 2002. (Also available from: http://www.nihcm.org/innovations.pdf)
11. Health Action International, World Health Organization. Medicines prices: a new approach to measurement. Geneva: World Health Organization; 2003. WHO document WHO/EDM/PAR/2003.2.
12. Henry D, Lexchin J. The pharmaceutical industry as a medicines provider. Lancet 2002;360:1590-5.
13. Hunt M. Prescription drugs and intellectual property protection: finding the right balance between access and innovation. Washington (DC): National Institute for Health Care Management; 2000. (Also available from: http://www.nihcm.org/pharm.html)
14. National Institute for Health Care Management. Prescription drug expenditures in 2001: another year of escalating costs. Washington (DC) National Institute for Health Care Management; 2002. (Also available from: http://www.nihcm.org/spending2001.pdf)
15. Correa C. Integrating public health concerns into patent legislation in developing countries. Geneva: South Centre; 2001. (Also available from: http://www.southcentre.org/publications/publichealth/publichealth.pdf)
16. International Marketing Service. Improved outlook for Latin America, 1999-2004, London: International Marketing Service; 2003. (Also available from: http://www.ims-global.com/insight/news_story/news_story_0002015.htm)
17. World Trade Organization. Understanding the WTO: the organization. Members and observers, 2002, Available from: http://www.wto.org/english/ thewto_e/whatis_e/tif_e/org6_e.htm
18. Thorpe P. Study on the implementation of the TRIPS Agreement by developing countries. London: Commission on Intellectual Property Rights; 2001 (Study Paper No. 7).
19. Bermudez JAZ. [Pharmaceutical industry, state and society: critical approach to the Medicines Policy in Brazil]. São Paulo: HUCITEC; 1995. In Portuguese.
20. Bermudez JAZ. [Medicines: health or industry? The production of medicines in Brazil]. Rio de Janeiro: Relume Dumará; 1992. In Portuguese.
21. [Decree No. 4.830, 4th September 2003. Changes to articles 1, 2, 5, 9 and 10 of Decree No. 3.201, 6th October 1999, regarding issuing of compulsory licences in cases of national emergency and public interest]. Brasilia, DF: Diário Oficial [da] República Federativa do Brasil; 5th September 2003. In Portuguese.
22. Abbott FM. Compulsory licensing for public health needs: the TRIPS agenda at the WTO after the Doha declaration on public health. Geneva: Friends World Committee for Consultation, Quaker United Nations Office; 2002 (Occasional Paper No. 9). (Also available from: http://www.geneva.quno. info/pdf/OP9.Abbott.pdf)
23. Creese A, Quick J. Working paper on differential pricing arrangements and feasibility: context setting paper. Geneva: World Health Organization; 2001.
24. Reichman JH, Hasenzahl C. Non-voluntary licensing of patented inventions: historical perspective, legal framework under TRIPS, and an overview of the practice in Canada and the USA. Geneva: International Centre for Trade and Sustainable Development, United Nations Conference on Trade and Development; 2003 (Issue Paper No. 5). (Also available from: http:// www.ictsd.org/pubs/ ictsd_series/iprs/CS_reichman_hasenzahl.pdf)
25. World Trade Organization. Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health, 2003. Available from: http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm
26. Fleck F. Drugs could still be costly under World Trade Organization deal. BMJ 2003; 327:639.
27. Bermudez JAZ, Oliveira MA. Essential medicines and AIDS care in Brazil: recent lessons learnt. In: Hammer S, Moati JP, N'Doye I, Binswanger H, Cahn P, Hira S, et al, editors. Improving access to care in developing countries: lessons from practice, research, resources and partnerships. Geneva: UNAIDS, WHO, Ministry of Foreign Affairs, France: 2002. p. 79-87.
28. Drahos P. Bilateralism in intellectual property. Washington (DC): Oxfam International; 2001. (Also available from: http://www.oxfam.org.uk/what_we_do/ issues/trade/bilateralism_ip.htm)